How to buy VIVUS stock

VIVUS, Inc is a biotechnology business based in the US. VIVUS shares (VVUS) are listed on the NASDAQ and all prices are listed in US Dollars. VIVUS employs 59 staff and has a trailing 12-month revenue of around USD$73.2 million.

VIVUS share price

Use our graph to track the performance of VVUS stocks over time.

VIVUS shares at a glance

• Key figures

Information last updated 2021-01-13.

52-week range	USD$0.0697 - USD$1.88
50-day moving average	USD$0.122
200-day moving average	USD$0.299
Wall St. target price	USD$1.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.596

Buy VIVUS shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy VIVUS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of VIVUS, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

VIVUS financials

Revenue TTM	USD$73.2 million
Gross profit TTM	USD$43.8 million
Return on assets TTM	-2.2%
Return on equity TTM	0%
Profit margin	-39.28%
Book value	$-4.93
Market capitalisation	USD$8.3 million

TTM: trailing 12 months

Shorting VIVUS shares

There are currently 3.0 million VIVUS shares held short by investors – that's known as VIVUS's "short interest". This figure is 488.8% up from 510,645 last month.

There are a few different ways that this level of interest in shorting VIVUS shares can be evaluated.

VIVUS's "short interest ratio" (SIR)

VIVUS's "short interest ratio" (SIR) is the quantity of VIVUS shares currently shorted divided by the average quantity of VIVUS shares traded daily (recently around 871468.69565217). VIVUS's SIR currently stands at 3.45. In other words for every 100,000 VIVUS shares traded daily on the market, roughly 3450 shares are currently held short.

However VIVUS's short interest can also be evaluated against the total number of VIVUS shares, or, against the total number of tradable VIVUS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VIVUS's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 VIVUS shares in existence, roughly 170 shares are currently held short) or 0.1704% of the tradable shares (for every 100,000 tradable VIVUS shares, roughly 170 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VIVUS.

Find out more about how you can short VIVUS stock.

Have VIVUS's shares ever split?

VIVUS's shares were split on a 1:10 basis on 11 September 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VIVUS shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for VIVUS shares which in turn could have impacted VIVUS's share price.

VIVUS share price volatility

Over the last 12 months, VIVUS's shares have ranged in value from as little as $0.0697 up to $1.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VIVUS's is -0.8493. This would suggest that VIVUS's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, VIVUS has bucked the trend.

VIVUS overview

VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Frequently asked questions

• What percentage of VIVUS is owned by insiders or institutions?

  Currently 7.089% of VIVUS shares are held by insiders and 19.065% by institutions.

• How many people work for VIVUS?

  Latest data suggests 59 work at VIVUS.

• When does the fiscal year end for VIVUS?

  VIVUS's fiscal year ends in December.

• Where is VIVUS based?

  VIVUS's address is: 900 East Hamilton Avenue, Campbell, CA, United States, 95008

• What is VIVUS's ISIN number?

  VIVUS's international securities identification number is: US9285513084

• What is VIVUS's CUSIP number?

  VIVUS's Committee on Uniform Securities Identification Procedures number is: 928551100